



**Contra Costa Health Plan  
P&T Formulary Update  
December 12, 2025**

**Changes effective: 1/17/2026**

**Contra Costa Health Plan Pharmacy & Therapeutics (P&T) Committee Decisions**

*On December 12, 2025 the CCHP P&T Committee reviewed the following Therapeutic Classes, Drug Monographs and PA criteria for efficacy, safety, utilization, cost and safety:*

<b>Therapeutic Class Reviews</b>
<ul style="list-style-type: none"> <li>• Hereditary Angioedema treatments</li> <li>• PCSK9 Inhibitors</li> <li>• Blood Glucose Test Strips</li> <li>• Multivitamin Class</li> <li>• Topical Antivirals</li> <li>• Urinary Tract Antispasmodics</li> </ul>
<b>Drug Monographs</b>
<ul style="list-style-type: none"> <li>• Anzupgo (Delgocitinib)</li> <li>• Brinsupri (Brensocatib)</li> <li>• Zevaskyn (Prademagene zamikeracel)</li> </ul>
<b>Prior Authorization Criteria Updates</b>
<p><u>New criteria was created for the following agents:</u></p> <ul style="list-style-type: none"> <li>• Hereditary Angioedema (HAE) Treatments</li> <li>• Anzupgo (Delgocitinib)</li> <li>• Brinsupri (Brensocatib)</li> <li>• <u>Wegovy</u> MASH criteria</li> </ul> <p><u>Updates were made to the criteria for the following agents:</u></p> <ul style="list-style-type: none"> <li>• Denosumab (Prolia), Denosumab (Xgeva)</li> <li>• Kerendia</li> <li>• Ohtuvayre (ensifentrine)</li> <li>• Rezdifra (resmetirom)</li> </ul> <p><b><u>Formulary updates</u></b></p> <ul style="list-style-type: none"> <li>• Over-the-counter medications</li> </ul> <p><u>Criteria reviewed and unchanged:</u></p> <ul style="list-style-type: none"> <li>• Blood Glucose Test Strips</li> <li>• Multivitamins</li> <li>• Topical Antivirals</li> </ul>

<ul style="list-style-type: none"> <li>Urinary Tract Antispasmodics</li> </ul>	
<b>Guest Speaker(s)</b>	
<ul style="list-style-type: none"> <li>None</li> </ul>	
<b><u>CCHP P&amp;T Committee approved the following modifications to the formulary (commercial and BHC members):</u></b>	
<b>Medication Name &amp; Dosage Strength</b>	<b>Approved Formulary Changes</b>
Cinryze 500unit (c1 esterase inhibitor)	Remove from formulary to non-formulary
Orladeyo (berotralstat) 110mg, 150mg capsule	Add to formulary requiring PA for commercial
Haegarda (c1 esterase inhibitor, human) 2,000unit, 3,000units	Add to formulary requiring PA for commercial
Bildyos (denosumab)	Add to formulary requiring PA
Bilprevda (denosumab)	Add to formulary requiring PA
Ofev 100mg, 150mg capsule	Add to formulary requiring PA
Malathion External Lotion 0.5%	Add to formulary requiring PA
<b>New Product Reviews (including new indications)</b>	
<ul style="list-style-type: none"> <li>Kerendia (finerenone)</li> <li>Penmenvy</li> <li>Orlynvah (sulopenem etzadroxil-probenecid)</li> <li>Orquidea (norethindrone)</li> <li>Gonal-f RFF (follitripin alfa)</li> <li>Egrifta WR (tesamorelin)</li> <li>Anzupgo (delgocitinib)</li> <li>Brinsupri (brensocatib) tablet</li> <li>Jaythari (deflazacort) tablet</li> <li>Wayrilz (rilzabrutinib) tablet</li> <li>Blujepa (gepotidacin) tablet</li> <li>Zelvysia (sapropterin) oral packet</li> </ul>	<ul style="list-style-type: none"> <li>Pyzchiva (ustekinumab-ttwe)</li> <li>Analpram HC (hydrocortisone-pramoxine)</li> <li>Hernexeos (zongertinib)</li> <li>TNKase (Tenecteplase) kit</li> <li>Prezcobix (cobicistat-darunavir) oral tablet</li> <li>Modeyso (dordaviprone) oral capsule</li> <li>Brukinsa (Zanubrutinib) tablet</li> <li>Dawnzera (donidalorsen)</li> <li>Unloxcyt (csibelimab-ipdl)</li> <li>Lurbiro (flurbiprofen) tablet</li> <li>Doptelet (avatrombopag)</li> </ul>